Incorporating biomarkers into cancer and aging research.


Journal Article (Review)

The challenge in treating the older adult with cancer is accurately accounting for and adapting management to the heterogeneity in health status of the individual patient. Many oncologists recognize that chronological age alone should not be the determinant when deciding on a treatment regimen. Easily measurable markers that provide an assessment of functional age would be ideal to assess frailty, which may predispose the patient to complications from cancer treatment, including increased toxicity, functional decline, decreased quality of life, and poorer survival. Several categories of potential markers, including chronic inflammatory markers, markers of cellular senescence, and imaging to assess muscle mass to detect sarcopenia, may provide insight into the likelihood of treatment-related complications. This article discusses candidate markers and strategies to evaluate these markers in cancer treatment trials, with the aim of developing a method to assess risk of oncologic outcomes and guide management decisions for both the physician and patient.

Full Text

Duke Authors

Cited Authors

  • Hubbard, JM; Cohen, HJ; Muss, HB

Published Date

  • August 20, 2014

Published In

Volume / Issue

  • 32 / 24

Start / End Page

  • 2611 - 2616

PubMed ID

  • 25071114

Pubmed Central ID

  • 25071114

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.55.4261


  • eng

Conference Location

  • United States